Multiple Myeloma Treatment at John Theurer Cancer Center in New Jersey

You will have access to the latest medical therapies for multiple myeloma, including medications developed through our research, such as thalidomide, lenalidomide, pomalidomide, bortezomib, carfilzomib, elotuzumab, daratumumab, and more.

John Theurer Cancer Center is one of the few centers worldwide offering CAR T-cell therapy for multiple myeloma. This breakthrough immunotherapy uses your own immune cells to target and destroy cancer cells. Patients who had relapsed after prior treatments have achieved long-term remission through CAR T-cell therapy. Learn more about CAR T-Cell therapy. 

Our team has pioneered the use of advanced immunotherapy for multiple myeloma, including T-cell engagers, antibody-drug conjugates, and checkpoint inhibitors. These therapies activate your immune system to find and eliminate cancer cells.

If you have been diagnosed with smoldering multiple myeloma or MGUS (monoclonal gammopathy of undetermined significance), we offer personalized surveillance to monitor your condition. Our team will guide you on whether treatment is necessary and provide access to clinical trials focused on early detection and optimal treatment timing.

At John Theurer Cancer Center, we have one of the largest blood and marrow stem cell programs in the country, performing over 250 transplants annually for multiple myeloma. Our center specializes in autologous and allogeneic stem cell transplants, with a focus on reducing complications and lowering the risk of cancer recurrence. We are global leaders in combining checkpoint inhibitors with stem cell transplantation, providing patients with the most advanced care available. Our Blood and Marrow Stem Cell Transplant Program.